Genomics is a key element in the potential of precision medicine to transform oncology. Hybrid-capture based targeted next-gen sequencing (NGS) represents a particularly promising option for cancer genomic testing, as it enables the profiling of all cancer-relevant events with the advantage of being compatible with formalin-fixed, paraffin-embedded (FFPE) tissue.
The Glasgow Precision Oncology Laboratory (GPOL) has defined the content required to capture the full range of clinically and biologically important genomic events that characterize solid tumors and turned these into a range of SureSelect cancer NGS assays, the first of which, dubbed Cancer Core, will be presented during this webinar.
In this webinar, Dr. Cooke, head of Medical Genomics of the GPOL shares:
- How the GPOL has built affordable, fit-for-purpose, cancer NGS solutions using the SureSelect target enrichment platform, specifically to address the challenges of real-world oncology.
- How the GPOL is implementing broad genomic testing as part of its mission to accelerate the translation of novel cancer therapeutics from discovery to clinical applications.
For Research Use Only. Not for use in diagnostic procedures.